Main idea: Endostatin is a physiological signal molecule that is involved in angiogenesis and impacts neurogenesis. Therapy based on endostatin regulation may lead to improvement of neuropathy symptoms.
Abstract: For over a decade, diabetic neuropathy has exhibited great emergence in diabetic patients. There are numerous impediments in understanding the underlying pathology that it is not that enough to conclude. Initially, there was no intricate protocol for diagnosis as its symptoms mimic most of the neurodegenerative disorders and demyelinating diseases. Continuous research on this reveals that many pathological correlates are also detectable clinically. The most important pathologic manifestation is imbalanced angiogenesis/neovascularization. This review is completely focused on establishing pathogenesis and anti-angiogenic agents which are physiological signal molecules. These agents can also be used externally to inhibit those pathogenic pathways. Pathologically, diabetic neuropathy (DN) demonstrates the imbalanced expression of many knotty factors. Their pathway towards the incidence of DN is quite interrelated. Many anti-angiogenic agents inhibit neovascularization to many extents, but out of them, predominant inhibition of angiogenic activity is shared by endostatin which is now in clinical trial phase II. It inhibits almost all angiogenic factors because they share interrelated pathogenesis towards imbalanced angiogenesis. Endostatin is a physiological signal molecule produced by the proteolytic cleavage of collagen XVIII. It has also a broad research profile in the field of medical research and further investigation can show promising therapeutic effects for the benefit of mankind.